Patent · US Active

Anti-TGF-beta antibodies and their use

US11242384B2 · kind B2 · utility

2Cited by

12References

14Claims

0Family size

Assignee

Sanofi · FR

Inventors

Gary Shapiro · Arlington, US
Kevin Brower · Bound Brook Junction, US
Patrick Finn · North Riverside, US
Richard C. Gregory · Framingham, US
Rao Koduri · Shrewsbury, US
Feng Liu · Sunnyvale, US
Natalia Malkova · Needham, US
Parminder Mankoo · Foster City, US
Jack R. Pollard · Acton, US
Huawei Qiu · Westborough, US
Joachim Theilhaber · Cambridge, US
Christopher Winter · Swampscott, US
Marcella Yu · Medford, US

Key dates

Filing date	Jul 16, 2020
Grant date	Feb 8, 2022
Priority date	—
Expiry date	Jul 16, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.